Technological Growth Analysis and Challenges of Precision Cardiology Industry
Researchers and physicians have been able to utilize knowledge about underlying mutations and alterations, have triggered the beginning and progression of several cardiovascular diseases, with potentially life-threatening implications, thanks to advances in sequencing technologies. This has aided stakeholders in discovering new genetic biomarkers for guiding therapeutic decisions to patients with complex cardiovascular conditions.
Furthermore, considerable research is being performed to enhance the development of new biomarkers that might one day be utilized to identify cardiovascular problems, allowing for precision medicine in cardiology.
Significant advancements in sequencing technology tools have made it possible to conduct an increasing number of cardiovascular genetic investigations.
As the next frontier of precision medicine, the global precision cardiology market has immense potential to change the area of cardiovascular disease diagnostics, which is expected to assist stakeholders in lessening the burden associated with these disorders.
According to BIS Research, the global market for precision cardiology is predicted to grow at a CAGR of 12.90% over the forecast period of 2021–2031.
Growth Analysis of the Technologies
As one can see from this chart, sequencing led the global precision cardiology market (2020 and 2031). This is mostly due to the increased use of next-generation sequencing (NGS) for precision cardiology testing to diagnose cardiovascular diseases (CVDs) and the use of such technologies in various cardiovascular genomic research initiatives.
Furthermore, clinical benefits of NGS, including complete coverage, sample multiplexing, and improved sensitivity, have aided the expansion of the overall sequencing sector in the global precision cardiology market.
Next-generation sequencing (NGS) technologies are examples of sequencing technology. With NGS, the market for these technologies in the precision cardiology ecosystem is expected to grow in the future due to underlying benefits such as fast turnaround time and high resolution.
Furthermore, the rising trend of using complete gene panels for precision cardiology testing is expected to drive the growth of NGS in the global precision cardiology market.
With the increasing adoption of government-supported research programs in cardiology genetic testing for the development of new genetic biomarkers, the growth of PCR and microarray is likely to accelerate in the coming years.
Growing Challenges in the Gateway of Precision Cardiology Industry
Limited high-complexity testing centers: With the continued rapid improvements, modern technologies utilized for precision cardiology testing necessitate considerable capital investment to enable scale operation and competitive pricing points.
Since physicians in developing countries continue to rely on traditional methods to detect cardiovascular diseases (CVDs), such as an electrocardiogram (ECG), conventional blood tests, and cardiac computerized tomography (CT) scan, the amount of genomic sample obtained from patients is insufficient to scale-up the operation. Furthermore, there is difficulty in developing and sustaining several technological platforms.
Many medical research facilities lack the necessary capital to develop the infrastructure for contemporary genetic testing, including precision cardiology assessments and its subsequent complete interpretation, especially given the current funding situation.
More importance to standard cardiovascular disease (CVD) tests: Traditional blood-based protein tests and imaging approaches for screening and diagnosing CVD is widely utilized. Precision cardiology tests, also known as cardiology genetic testing, efficiently examine underlying genetic mutations linked with CVDs such as arrhythmia, cardiomyopathy, aortopathy, and congenital heart diseases.
Precision cardiology products and services are expected to provide the best possible patient care. Traditional screening modalities such as the electrocardiogram (ECG), conventional blood tests, and cardiac computerized tomography (CT) scan, among others, remain the most widely used source for clinical analysis of several cardiovascular diseases, particularly by clinicians in developing economies.
Clinicians continue to choose traditional blood-based protein biomarker tests, such as the troponin test and electrocardiogram (ECG), over other additional possibilities. Therefore, clinicians choose conventional methods over emerging alternatives whenever they have limited or no confidence in other advanced cardiovascular tests.
To summarize, precision medicine is highly recognized as one of the most prominent approaches to enhancing the quality of diagnosis and treatment by considering a person’s biological and clinical characteristics based on stratification.
With the technology evolution, manufacturers and service providers are actively utilizing the potential of these technologies to offer the best solutions to clinicians for the diagnosis of cardiovascular diseases (CVDs) by analyzing underlying genetic biomarkers.
Do you want to discover more about emerging technologies? BIS Research provides the most recent market insights and analyses. To learn more, please contact us at hello@bisreseach.com.
